FAQ / READOUT
KPV peptide: frequently asked questions.
Direct answers from the research literature and the audited FDA reference — with every quantitative claim cited and every human-data gap stated plainly.
What is KPV peptide?
KPV is the C-terminal tripeptide — lysine-proline-valine, residues 11-13 — of alpha-MSH, studied for anti-inflammatory activity without the parent hormone's pigmentary action [4]. It is a single research peptide, not a blend, and not an approved drug or supplement [14].
What does KPV peptide do?
In research models KPV dampens inflammation by suppressing NF-kB and MAP-kinase signaling and reducing pro-inflammatory cytokine secretion across epithelial and immune cells [1]. In the gut it enters cells via the PepT1 transporter, which is upregulated in inflamed tissue [1]. These are cell and animal findings, not human outcomes.
What is KPV peptide used for?
In the literature KPV is studied chiefly for intestinal inflammation in colitis and inflammatory-bowel-disease models, with additional preclinical work in wound healing, skin, and antimicrobial settings [1] [2] [6]. It is research-only and is not an approved treatment for any condition [14].
What is KPV peptide good for?
Preclinical research has examined KPV for reducing colonic inflammation, supporting epithelial and mucosal-barrier integrity, and assisting tissue repair [1] [5] [6]. Human efficacy is not established — there are no human clinical trials, so "good for" describes what was tested in models, not a proven human benefit [14].
What are the benefits of KPV peptide?
The reported research benefits are anti-inflammatory: reduced colitis severity, lower myeloperoxidase and TNF-alpha, and accelerated re-epithelialization in a corneal model [2] [5] [6]. These are animal and in-vitro findings, not human outcomes, and no approved benefit claim exists [14].
How long does it take KPV peptide to work?
There is no human timeline. In a rabbit corneal model, KPV-treated corneas were fully re-epithelialized by 60 hours [6]; colitis-model benefits were measured over days of continuous dosing [1]. None of these model timelines translates to a human onset.
Is KPV peptide worth it?
That is not a question this literature can answer. KPV has no human clinical trials, no validated human dose, and no approved status [14]. Its value at present is as a research peptide with a reproducible preclinical anti-inflammatory signal — a research tool, not a proven human product.
Can you take KPV and BPC-157 together?
No controlled study has evaluated a KPV plus BPC-157 combination in humans. The KPV literature studies it as a single tripeptide or co-formulated with specific research agents in nanoparticles — for example with FK506 or rapamycin — not as a human stack [12] [13]. There is no safety or efficacy basis for combining them in people.
How quickly does KPV peptide work?
Onset is model-dependent and undefined for humans. Free KPV is rapidly degraded by peptidases, which is why much recent work uses nanoparticle or hydrogel formulations to extend its residence time [5] [9] [14]. No validated human pharmacokinetics exist to define a speed of action.
What is KPV?
KPV stands for the amino-acid sequence lysine-proline-valine (Lys-Pro-Val), a linear tripeptide that is the C-terminal fragment of alpha-melanocyte-stimulating hormone [4]. Its molecular formula is C16H30N4O4, molecular weight 342.44 Da, CAS 67727-97-3.
How is KPV related to alpha-MSH?
KPV is the C-terminal tripeptide (residues 11-13) of alpha-MSH [4]. It retains the parent hormone's anti-inflammatory activity but lacks its melanogenic (pigmentary) action, and its anti-inflammatory effect appears largely melanocortin-receptor-independent [2] [4].
What is the molecular structure of KPV?
KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine, sequence H-Lys-Pro-Val-OH. Molecular formula C16H30N4O4, molecular weight 342.44 Da, CAS number 67727-97-3, PubChem CID 125672.
Is KPV peptide safe?
Human safety is unestablished. There are no published human clinical trials and no validated human pharmacokinetics; KPV is handled as a research-only peptide and is not intended for human consumption [14]. The absence of reported side effects reflects the absence of human study, not demonstrated safety.
Who should not take KPV peptide?
KPV is not an approved drug or supplement and is not intended for human consumption, so the research literature does not define human eligibility or contraindications [14]. Questions about personal suitability are clinical questions for a licensed prescriber, not ones this preclinical literature can answer.
Can you take KPV every day?
No human dosing schedule exists. Animal studies used continuous oral delivery — for example ~100 uM in drinking water in mice — or repeated topical dosing [1] [6]; none of this translates to a human daily dose [14].
How often do I inject KPV peptide?
There is no established human injection regimen. Research routes have been oral (drinking water, nanoparticle-encapsulated), topical (ocular drops, dressings), and local delivery — not validated human injection [1] [5] [6]. The literature does not define an injection frequency for people.
How long should I take KPV peptide for?
No human treatment duration has been defined. Animal colitis studies dosed over the course of the disease model — days to weeks — but those are model protocols, not human regimens [1] [2].
What is KPV peptide dosage?
Research doses include ~10 nM in vitro, ~100 uM oral in mouse colitis, and 1-10 mg/mL topical eye drops in rabbits [1] [6]. No established or validated human research dose exists [14]. See the dosage page for the full research context.
What are KPV peptide side effects?
A human side-effect profile is not established because no human trials exist [14]. Safety conclusions cannot be drawn from the current in-vitro and animal literature, which was designed to test mechanism and efficacy in models rather than human tolerability.
Does KPV cause skin pigmentation or tanning like other melanocortins?
No. KPV's defining feature in the literature is that it retains alpha-MSH's anti-inflammatory action while lacking the pigmentary (melanogenic) effect, and its activity is largely melanocortin-receptor-independent [3] [4]. It is not a tanning agent.
How does KPV reduce inflammation?
It suppresses NF-kB nuclear translocation and MAP-kinase signaling and reduces pro-inflammatory cytokine secretion [1]. In the gut it enters epithelial cells via the PepT1 transporter, which is upregulated in inflamed tissue [1], and its action appears largely independent of melanocortin receptors [2] [3].
Is KPV legal?
KPV is not an FDA-approved drug and is sold as a research chemical for laboratory use, not as a medicine or supplement [14] [17]. It is individually named on the agenda of an FDA advisory-committee meeting set for July 23-24, 2026, as a substance being considered for the 503A bulks list — a scheduled evaluation, not a decision or a change in status [19]. See the legal-status page for the full FDA-sourced detail.
Can you get KPV from a compounding pharmacy?
A bulk drug substance may be used in 503A compounding only if it has a USP/NF monograph, is a component of an FDA-approved drug, or is on FDA's 503A bulks list; otherwise it must be nominated and evaluated [17]. KPV is currently under FDA evaluation (scheduled for the July 2026 PCAC meeting) rather than on the bulks list [19]. This site names no pharmacy and gives no procurement guidance; see the legal-status page.
What is the FDA 503A status of KPV?
KPV is a research peptide that is not FDA-approved and is scheduled for FDA Pharmacy Compounding Advisory Committee evaluation as a candidate for the 503A bulks list at the July 23-24, 2026 meeting [19]. The audited FDA reference does not assign KPV a numbered 503A category, so this site states none — its present status is "scheduled for PCAC evaluation" [17] [19].